share_log

QSAM Biosciences Receives Clearance From FDA To Expand Enrollment Criteria In Its Phase 1 Study Of CycloSam Targeting Metastatic Bone Cancer

QSAM Biosciences Receives Clearance From FDA To Expand Enrollment Criteria In Its Phase 1 Study Of CycloSam Targeting Metastatic Bone Cancer

QSAM 生物科學獲得 FDA 的許可,以擴大其針對轉移性骨癌的環狀藥的第一階段研究的註冊標準
Benzinga ·  2023/03/08 08:05

QSAM Biosciences Receives Clearance From FDA To Expand Enrollment Criteria In Its Phase 1 Study Of CycloSam Targeting Metastatic Bone Cancer

QSAM Biosciences獲得FDA批准擴大其針對轉移性骨癌的CyclSam第一階段研究的入選標準

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論